IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24CRBP&src=ctag” target=”_blank”gt;$CRBPlt;/agt; lt;a href=”https://twitter.com/hashtag/ClassAction?src=hash” target=”_blank”gt;#ClassActionlt;/agt;–The
Schall Law Firm
, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against Corbus
Pharmaceuticals Holdings, Inc. (“Corbus” or “the Company”) (NASDAQ: CRBP)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.

Investors who purchased the Company’s shares between November 14, 2016
and February 28, 2019, inclusive (the “Class Period”), are encouraged to
contact the firm before May 13, 2019.

If you are a shareholder who suffered a loss, click
here to participate
.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm’s website at www.schallfirm.com,
or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading
statements to the market. Corbus inappropriately changed the primary
efficacy endpoint of its clinical trial for its drug candidate
Lenabasum. The change took place after the trial’s results were
unblinded to the Company. Corbus replaced the two-sided p-value
traditionally reported in clinical trials with a one-sided p-value, in
an effort to conceal the study result’s lack of statistical
significance. Based on these facts, the Company’s public statements were
false and materially misleading throughout the class period. When the
market learned the truth about Corbus, investors suffered damages.

Join
the case
to recover your losses.

The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights
litigation.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
www.schallfirm.com
Office:
310-301-3335
Cell: 424-303-1964
info@schallfirm.com